Global Infantile Spasms Therapeutics Market

Download free Sample

Infantile spasms therapeutics are used for the treatment of seizures or an epilepsy syndrome in young children, usually aged one year or below. Infantile spasm refers to sudden stiffening of the body, the arms, and the legs or forward bending of the head. Primary treatments for infantile spams include steroid therapy and an anti-seizure medicine called Sabril. Infantile spasms are also known as the West syndrome, as the disease was first defined by Dr. William James West in the 1840s. These spasms generally begin in the first year of life, between three and eight months of age, and occur in two to three out of every 10,000 babies. The disorder is more common in boys than girls. Family history is another cause– about 3% to 6% of cases can be linked to family history. The diagnosis of infantile spasms is carried out by physical and neurological examination, laboratory tests such as MRI of the brain, and blood and urine tests. Medication includes monotherapy as well as combination therapy. In approximately 20%–50% of the patients, infantile spasms evolve into the Lennox-Gastaut syndrome. Conversely, a similar percentage of patients with the Lennox-Gastaut syndrome have a history of infantile spasms
The Infantile Spasms Therapeutics market has witnessed a growth from USD XX million to USD XX million from 2017 to 2022. With a CAGR of X.X%, this market is estimated to reach USD XX million in 2029.

The report focuses on the Infantile Spasms Therapeutics market size, segment size (mainly covering product type, application, and geography), competitor landscape, recent status, and development trends. Furthermore, the report provides strategies for companies to overcome threats posed by COVID-19.

Technological innovation and advancement will further optimize the performance of the product, enabling it to acquire a wider range of applications in the downstream market. Moreover, customer preference analysis, market dynamics (drivers, restraints, opportunities), new product release, impact of COVID-19, regional conflicts and carbon neutrality provide crucial information for us to take a deep dive into the Infantile Spasms Therapeutics market.

Major Players in the Infantile Spasms Therapeutics market are:
ORPHELIA Pharma
Mallinckrodt Pharmaceuticals
Retrophin
INSYS Therapeutics
GW Pharmaceuticals
Valerion Therapeutics
Anavex Life Sciences
Catalyst Pharmaceuticals
H. Lundbeck

On the basis of types, the Infantile Spasms Therapeutics market is primarily split into:
Monotherapy
Combination Therapy

On the basis of applications, the market covers:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies